AGEN1884

Phase 2Small molecule

AAgenus Inc.

AGEN1884 is one of 48 small molecule programs targeting Cervical Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical CancerActive, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

115 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

45 2

Avastin

Roche

Phase 3

22 3

Paraplatin

AAvyxa

Phase 3

36 4

Keytruda

Merck & Co.

Phase 3

12 5

Trodelvy

Gilead

Phase 3

5 6

Lenvima

Eisai

Phase 3

3 7

Taxotere

AAvyxa

Phase 3

6 8

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

2 9

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 3

2 10

Rescue

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cervical Cancer2 trials

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Active, not recruiting·AAgenus Inc.·Phase 2·NCT03894215·212 enrolled

A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors

Completed·AAgenus Inc.·Preclinical·NCT03495882·175 enrolled

Pembrolizumab1 trial

Study of AGEN1884 With Pembrolizumab in 1L NSCLC

Terminated·AAgenus Inc.·Phase 2·NCT03411473·2 enrolled

Angiosarcoma1 trial

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Withdrawn·AAgenus Inc.·Phase 2·NCT04607200

Bladder Cancer1 trial

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Terminated·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT04430036·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AGEN1884. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AGEN1884 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AGEN1884. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Agenus Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAgenus Inc.

AGEN1884

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cervical Cancer2 trials

Pembrolizumab1 trial

Angiosarcoma1 trial

Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News